Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII-Reference-Cited by-同舟云学术

Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII

Published:2017-02-22 Issue:3 Volume:15 Page:411-419
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Reding M. T.¹,Ng H. J.²,Poulsen L. H.³,Eyster M. E.⁴,Pabinger I.⁵,Shin H.-J.⁶,Walsch R.⁷,Lederman M.⁸,Wang M.⁸,Hardtke M.⁹,Michaels L. A.⁸

Affiliation:

1. University of Minnesota Medical Center; Minneapolis MN USA

2. Department of Haematology; Singapore General Hospital; Singapore

3. Centre for Haemophilia and Thrombosis; Aarhus University Hospital; Aarhus Denmark

4. Penn State Hershey Medical Center; Hershey PA USA

5. Division of Haematology and Haemostaseology; Department of Medicine I; Medical University of Vienna; Vienna Austria

6. Division of Hematology-Oncology; Department of Internal Medicine; School of Medicine, Medical Research Institute; Pusan National University Hospital; Busan Korea

7. Bayer Vital GmbH; Leverkusen Germany

8. Bayer; Whippany NJ USA

9. Bayer Pharma AG; Berlin Germany

Funder

Bayer Pharma AG, Leverkusen, Germany

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13597/fullpdf

Reference28 articles.

1. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

2. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study);Gringeri;J Thromb Haemost,2011

3. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) https://www.hemophilia.org/sites/default/files/document/files/241Prophylaxis.pdf

4. Guidelines for the management of hemophilia;Srivastava;Haemophilia,2013

5. Practice patterns in haemophilia A therapy - global progress towards optimal care;Geraghty;Haemophilia,2006

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review;Drugs in R&D;2024-08-20

2. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A;Blood Advances;2024-05-30

3. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII;Acta Haematologica;2024-04-23

4. Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada;Haemophilia;2024-02-20

5. Next-generation therapeutics for rare genetic disorders;Mutagenesis;2024-02-09